- Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance.
- If COVID-19 is the true source of Ingrezza headwinds, quarterly sales growth could be under pressure through at least mid-2021.
- The DSMB has recommend a suspension of dosing in the RESTORE-1 Phase II Parkinson's study of NBib-1817.
- The FDA wants more data on dosing for the proposed Phase II study of NBI-921352 in pediatric SCN8A-DEE, pushing the trial start into Phase II.
- Although NBIX shares look meaningfully undervalued now, a few quarters of weak Ingrezza growth and no meaningful positive pipeline updates could continue to limit share price performance.
For further details see:
Neurocrine Biosciences Hit By Multiple Setbacks